Skip to content

Cencora COR Cash & Equivalents

Cash & Equivalents at other companies

Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
Cardinal Health logo
Cardinal HealthCAH
$3.94B+18.4%
McKesson logo
McKessonMCK
$3.98B-33.3%
United Parcel Service, Inc. logo
United Parcel Service, Inc.UPS
$5.8B+20.8%
CryoPort, Inc. logo
CryoPort, Inc.CYRX
$272.91M+656%
AbbVie logo
AbbVieABBV
$9.39B+81.5%

Other financials

Income statement

See full
Revenue$78.4B+3.8%
Gross profit$3.6B+17.3%
Operating income$1.1B+10.3%
Net income$1.6B+129%
EPS (diluted)$8.40+128%

Balance sheet

See full
Total debt$12.2B+71.9%
Total equity$3.4B+235%
Total assets$81.7B+14.7%

Cash flow

See full
Operating cash flow-$2.3B+15.2%
CapEx$165.6M+28.3%
Free cash flow-$2.4B+14.2%

Valuation

See full
Market cap$55.83B-1.9%
Enterprise value$65.84B+6.1%
P/E15.5×+3.1×
P/S0.2×0.0×

Profitability

See full
Gross margin3.8%+0.4pp
Operating margin0.8%0.0pp
Net margin0.6%-0.1pp
FCF margin1.1%+1.0pp

Returns & leverage

See full
Return on equity130.6%-99.8pp
Debt / equity3.6×-3.4×
Current ratio0.9×+0.1×

Where this comes from

Reported directly by Cencora in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Cencora’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cencora's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cencora's cash & equivalents?
Cencora (COR) reported cash & equivalents of $2.18B in Q1 2026.
How has Cencora's cash & equivalents changed year-over-year?
Cencora's cash & equivalents increased by 10.0% year-over-year, from $1.98B to $2.18B.
What is the long-term trend for Cencora's cash & equivalents?
Over 5 years (2020 to 2025), Cencora's cash & equivalents has grown at a -1.1% compound annual growth rate (CAGR), from $4.6B to $4.36B.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.